AstraZeneca PLC
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BZ0DK8
AZN
AstraZeneca PLC
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Drug Manufacturers—General
NAME
AstraZeneca PLC
ISIN
US0463531089
TICKER
AZN
MIC
XNAS
REUTERS
AZN.OQ
BLOOMBERG
AZN US
F&G:
70
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 13.05.2025
AstraZeneca
US0463531089
AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025.
With more than 75 abstracts, including eight late-breakers, the Company continues to drive inno...
AstraZeneca
Fr., 09.05.2025
AstraZeneca
US0463531089
Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive ...
AstraZeneca
Mi., 07.05.2025
AstraZeneca
US0463531089
Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin an...
AstraZeneca
Fr., 02.05.2025
AstraZeneca
US0463531089
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically mea...
AstraZeneca
Mo., 21.04.2025
AstraZeneca
US0463531089
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzuma...
AstraZeneca
Mo., 31.03.2025
AstraZeneca
US0463531089
Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not...
AstraZeneca
Mo., 31.03.2025
AstraZeneca
US0463531089
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).
The approval was granted by the...
AstraZeneca
Mi., 26.03.2025
AstraZeneca
US0463531089
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include...
AstraZeneca
Fr., 14.03.2025
AstraZeneca
US0463531089
AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife — and cancer survivor.
This press release features multimedia. View the full release here: https...
AstraZeneca
Fr., 07.03.2025
AstraZeneca
US0463531089
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint ...
AstraZeneca
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
